Xinlitai announced on December 8 that the company's pharmaceuticals, Xinlitan®, were newly included in the category B scope of the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” through negotiations, and Enalol® was successfully renewed in the medical insurance catalogue; Xinlitan adjusted to regular medical insurance catalogue management. Forlitan® and Xinlitine have been included in the medical insurance catalogue through negotiations in the early stages. They are still within the validity period of the agreement and fall within the scope of medical insurance category B.

Xinlitai announced on December 8 that the company's pharmaceuticals, Xinlitan®, were newly included in the category B scope of the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” through negotiations, and Enalol® was successfully renewed in the medical insurance catalogue; Xinlitan adjusted to regular medical insurance catalogue management. Forlitan® and Xinlitine have been included in the medical insurance catalogue through negotiations in the early stages. They are still within the validity period of the agreement and fall within the scope of medical insurance category B.